Comparing the current results to its competitors, Adverum Biotechnologies Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.12 %, recorded in the same quarter.
Adverum Biotechnologies Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 13.8 %
Adverum Biotechnologies Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes larger pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions, governmental agencies, and public and private research organizations. Its Ixo-vec gene therapy candidate for wet age-related macular degeneration (AMD) competes with various treatment modalities such as biologics, small molecules, long-acting delivery devices, and gene therapies. Established anti-VEGF therapies, including off-label bevacizumab and Eylea, are widely accepted as standard care for wet AMD. Competitors identified in company filings include Kodiak Sciences, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Regeneron, REGENXBIO, and Roche. These competitors may possess greater financial, technical, and human resources, more extensive experience in product development and regulatory approval processes, and treatments that could be more effective, have fewer side effects, or benefit from stronger marketing efforts, which may affect the company's market position.
March 3, 2025
Innovative Advances in Gene Therapy: Adverum Biotechnologies Initiates Pivotal ARTEMIS Phase 3 Study for Wet AMD Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a pioneer in the field of gene therapy, has taken a significant step forward in the management of wet age-related macular degeneration (AMD) with the initiation of its ARTEMIS Phase 3 study. This groundbreaking trial aims to assess the efficacy and safety of Ixo-vec (ixoberogene soroparvovec), a one-time intravitreal (IVT) injection designed to address the urgent needs of patients suffering from this debilitating ocular disease. Understanding Wet AMD and the Importance of Innovative TherapiesWet AMD is a leading cause of vision loss among the elderly p...
April 25, 2025
Adverum Biotechnologies, Inc. Under Investor Scrutiny Amidst Comparatively Stagnant Performance Pomerantz Law Firm, a highly respected and longstanding authority in securities litigation, has recently announced an investigation on behalf of investors in Adverum Biotechnologies, Inc. This investigation serves to delve into potential claims concerning the company, particularly centered on investor grievances. Interested parties are encouraged to reach out to Danielle Peyton at Pomerantz for further guidance and clarification.This scrutiny comes at a tumultuous time for Adverum Biotechnologies, marked by financial stagnation and contrasting performance metrics when placed alongside industry competitors. Analyzi...
November 18, 2024
Advancements in Gene Therapy for Wet AMD: Adverum Biotechnologies Sets a New Standard with Ixo-vec In an era where innovative therapies are paramount in managing ocular diseases, Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage biotech firm based in Redwood City, California, is at the forefront of redefining treatment options for wet age-related macular degeneration (AMD). The company recently announced compelling data from its LUNA and OPTIC clinical trials, showcasing the long-term efficacy and safety of its gene therapy candidate, Ixo-vec.The 52-week data from the LUNA trial, coupled with a substantial follow-up from the OPTIC trial extending to four years, bolster the argument for Ixo-vec ...
July 17, 2024
Positive Interim Results from Adverum Biotechnologies’ LUNA Phase 2 Trial Presented at 2024 ASRS Annual Meeting Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical trial for Ixo-vec (initially known as ADVM-022), at the 2024 Annual Meeting of the American Society of Retina Specialists (ASRS). Ixo-vec, a gene therapy product candidate intended for the treatment of wet age-related macular degeneration (wet AMD), has demonstrated significant promise in its 26-week analysis. Key Highlights of the 26-Week Interim Analysis Efficacy Data : The interim results highlight Ixo-vec s potential as a leading product candidate. Key efficacy metrics indicate substantial...
Publicly Traded Peers of Adverum Biotechnologies Inc
Alector Inc Share Performance
+60.78%
This Year
Alector Inc
Profile
Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.
Liquidia Corporation is a biopharmaceutical company that develops and commercializes products using its proprietary PRINT® technology to design and produce precision-engineered medicines. The company focuses on creating therapies for respiratory diseases and other areas of high unmet medical need, leveraging the potential of its unique particle engineering platform.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Sources:
Adverum Biotechnologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adverum Biotechnologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
